Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04516122 · ClinicalTrials.gov registry record
Bone Loss in Melanoma Survivors Receiving Immunotherapy
A clinical trial, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- 12
- Enrollment target
NCT04516122: Clinical Trial study, sponsored by M.D. Anderson Cancer Center.
NCT04516122 is a clinical trial that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04516122 was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- 12 participants
- Enrollment target
Study Summary
This study investigates the bone-related side effects caused by immunotherapy drugs such as nivolumab and pembrolizumab in patients with melanoma. Nivolumab and pembrolizumab are immunotherapy drugs (drugs that boost your immune system) used to prevent cancer from coming back in patients with melanoma. Specifically, researchers want to learn if there is any relationship between receiving immunotherapy and bone density (thickness) measured by a dual-energy X-ray absorptiometry (DXA) scan or bone turnover markers (which indicate levels of bone loss) found in the blood. This study may provide researchers with more information on bone loss and may help prevent bone loss in future patients.
Primary Outcome
Evaluated using dual X-ray absorptiometry (DXA).
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Dual X-ray Absorptiometry
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2021-05-10 |
| Est. Completion | 2025-06-18 |
Why NCT04516122 stopped before completion
NCT04516122 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 12 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Biospecimen Collection is the first listed.
NCT04516122 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04516122 about?
NCT04516122 is a clinical study titled "Bone Loss in Melanoma Survivors Receiving Immunotherapy". This study investigates the bone-related side effects caused by immunotherapy drugs such as nivolumab and pembrolizumab in patients with melanoma. Nivolumab and pembrolizumab are immunotherapy drugs (drugs that boost your immune system) used to prevent cancer from coming back in patients with melano...
What is the current status of trial NCT04516122?
This trial is currently terminated. The enrollment target is 12 participants. The study started on 2021-05-10. Estimated completion is 2025-06-18.
What interventions are being tested in trial NCT04516122?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Dual X-ray Absorptiometry (PROCEDURE).
Who is sponsoring clinical trial NCT04516122?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI